17 results about "Metoprolol" patented technology

The present invention relates to treatment of hypertension using a combination of tesofensine and metoprolol. The treatment is particularly well suited for the treatment of hypertensive obese subjects and hypertensive diabetic subjects.

The present disclosure relates to stable oral liquid pharmaceutical formulations comprising metoprolol or pharmaceutically acceptable salts thereof, methods of manufacturing the same, as well as applications thereof including the use of the inventive formulations for treatment of angina, hypertension, and myocardial infarction.

The invention relates to the field of medicine preparation, in particular to a compound composition and a preparation method and application thereof. The compound composition comprises a sustained-release layer, a blocking layer and a quick-release layer, the sustained-release layer comprises metoprolol and sustained-release layer auxiliary materials, the blocking layer comprises blocking layer auxiliary materials, the quick-release layer comprises amlodipine, metoprolol and quick-release layer auxiliary materials, and the mass ratio of metoprolol of the quick-release layer to metoprolol of the sustained-release layer is (1-3): (6.5-8.5). According to the compound composition, two antihypertensive drugs with complementary action mechanisms are prepared into the long-acting compound composition which is taken once a day, amlodipine and part of metoprolol are rapidly released, the rest metoprolol is slowly released within 24 hours, and rapid antihypertensive and long-acting antihypertensive requirements are met at the same time. The composition is stable in preparation process, convenient to produce and beneficial to industrial production.

The invention discloses an electrochemical sensor, a preparation method thereof, a detection system and application. The preparation method of the electrochemical sensor comprises the following steps: step 1, modifying a glassy carbon electrode with carbon nano onion; step 2, putting the glassy carbon electrode modified in the step 1 into a prepolymerization solution containing metoprolol for cyclic electropolymerization treatment; 3, the glassy carbon electrode treated in the step 2 is placed in a hydrochloric acid solution to be subjected to elution treatment, and the electrochemical sensor is obtained after elution is completed. Aiming at the technical bottleneck of rapid detection of metoprolol, the invention provides the electrochemical sensor, the electrochemical sensor shows excellent selectivity, repeatability and stability on metoprolol, the measurement has a wide linear range, the limit of detection (LOD) value is extremely low, and the electrochemical sensor can be used for detecting the concentration of metoprolol in metoprolol tablets or urine.

The application discloses a preparation method of a capillary electrochromatography open column based on chiral induction covalent organic framework modification, a product and application thereof. The application synchronously realizes chiral induction and acid catalysis through L-(+)-tartaric acid, generates permanent helical chirality of an achiral COF skeleton by relying on a chiral memory effect, and obtains a capillary electrochromatography open column which is excellent in thermal stability, acid and alkali tolerance and cyclic regeneration performance, can baseline separate eight kinds of clinical chiral drugs with large structural differences including amlodipine, propranolol, metoprolol, chlorpheniramine, clenbuterol, terbutaline, verapamil and isopropyl epinephrine, has no attenuation in separation effect for 50 times of sample injection in succession, can be prepared in a large scale, is suitable for routine detection of drug enterprises and hospital laboratories, and directly reveals an enantiomer recognition molecular mechanism through DFT quantitative calculation, thereby providing general theoretical guidance for directional design of high-performance chiral porous interface materials.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from enalapril, indapamide, metoprolol, amlodipine, folic acid and pharmaceutically acceptable auxiliary materials. The composition provided by the invention has the advantages that the composition has remarkable beneficial effects of reducing blood pressure and improving cardiac hemodynamics, and is particularly suitable for patients with hypertension secondary left ventricular hypertrophy and chronic heart failure. Meanwhile, the compound form of the product can improve the taking compliance of patients.

The present disclosure relates to stable oral liquid pharmaceutical formulations comprising metoprolol or pharmaceutically acceptable salts thereof, methods of manufacturing the same, as well as applications thereof including the use of the inventive formulations for treatment of angina, hypertension, and myocardial infarction.

The invention discloses a propofol-metoprolol twin drug as well as a preparation method and application thereof, the propofol-metoprolol twin drug is formed by connecting propofol and metoprolol, and the propofol-metoprolol twin drug is named as WSW-E01-166-P. According to the present invention, the WSW-E01-166-P can achieve the deanesthesia effect, and has good drug stability; the compound has relatively high inhibition efficiency on ICa-L, and shows an anti-arrhythmia effect in a barium chloride induced ventricular arrhythmia rat model. The novel twin drug WSW-E01-166-P disclosed by the invention has relatively good performance in the aspects of IVAs resistance, pharmacokinetics, toxicology and the like, and is greatly helpful for later promotion of entering a phase I clinical research process.

The invention belongs to the technical field of medical data processing, and provides a drug risk assessment system and method based on gene polymorphism, and the method comprises the steps: collecting historical medical data, carrying out the data preprocessing of the historical medical data, and carrying out the feature screening according to a specified screening rule; defining positive samples and negative samples based on the plurality of screened features, and establishing a training data set, specifically comprising: before establishing the training data set, performing oversampling on a small number of samples so that the number of the positive samples is equal to that of the negative samples; establishing a risk prediction model, and training the risk prediction model by adopting the training data set to obtain a trained risk prediction model; and inputting the drug dose and the test data of a to-be-evaluated object into the trained risk prediction model to obtain a risk evaluation result. According to the method, the risk condition of maintaining the dosage of the metoprolol is effectively evaluated.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine with the minimum hypertension treatment dosage of 20%-50%, valsartan with the minimum hypertension treatment dosage of 20%-50%, metoprolol with the minimum hypertension treatment dosage of 20%-50%, hydrochlorothiazide with the minimum hypertension treatment dosage of 20%-50%, homocysteine reducing medicine and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition is used for treating hypertension, is especially suitable for hypertension with heart failure, and can reduce the death risk of patients.

The present invention is related to an oral liquid formulation of metoprolol. The present invention is also related to an oral liquid formulation of metoprolol which comprises metoprolol or pharmaceut

The present invention relates to a method and a pharmaceutical composition for treating chronic kidney disease. The method and the pharmaceutical composition of the present invention relate to the combined use of doxazosin, pramipexole and metoprolol (or a pharmaceutically acceptable salt thereof), which can significantly improve chronic kidney disease, significantly reduce the urinary albumin excretion rate UACR, significantly improve the estimated glomerular filtration rate eGFR, and effectively delay the progression of renal function decline to end-stage renal failure.

Abstract The present invention relates to a method for modulating neuropathies. The method comprises: administering to a subject a therapeutically effective amount of doxazosin, a pharmaceutically acceptable salt or an acceptable form thereof, a therapeutically effective amount of pramipexole, a pharmaceutically acceptable salt or an acceptable form thereof, and a 5 therapeutically effective amount of metoprolol, a pharmaceutically acceptable salt or an acceptable form thereof. Abstract 20 26 20 52 65 03 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 2 6 5 0 3 J u l 2 0 2 6

This invention belongs to the field of medical data processing technology, and provides a drug risk assessment system and method based on gene polymorphism. The system includes: collecting historical medical data; preprocessing the historical medical data; and filtering features according to specified screening rules; defining positive and negative samples based on the selected features, and establishing a training dataset, specifically including: oversampling a small number of samples before establishing the training dataset to ensure that the number of positive and negative samples is equal; establishing a risk prediction model; training the risk prediction model using the training dataset to obtain a trained risk prediction model; and inputting the drug dosage and test data of the object to be assessed into the trained risk prediction model to obtain the risk assessment result. This invention effectively assesses the risk of metoprolol maintenance dosage.

This invention relates to polymorphs of metoprolol and its salts. Crystal forms and combinations thereof of the free base of metoprolol selected from polymorphs A, B, C, D, E, F, and G are disclosed, as well as crystalline polymorphs of salts of metoprolol. Pharmaceutical compositions containing one or more of these polymorphs and methods for preparing such polymorphs are also disclosed. Metoprolol can be used to treat a variety of diseases associated with low intracellular BH4 levels, such as phenylketonuria.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine, enalapril, metoprolol, folic acid substances and pharmaceutically acceptable auxiliary materials. The composition has the advantages that under the condition that the dosage of each component of the composition is lower than the lowest dosage for treating hypertension, the composition has a remarkable antihypertensive effect, so that the side effects of the medicine can be reduced. In addition, the compound form of the product can improve the taking compliance of patients.

Provided herein are methods of treating or preventing an arrhythmia in a cardiac graft patient, wherein the method comprises administering combinations of anti-arrhythmic agents (e.g., amiodarone, metoprolol, ivabradine, and / or mexiletine) to the subject in need thereof.